CEO SUMMARY: For pathologists and clinical, molecular, and genetic testing labs, appropriate reuses of lab data can provide a new source of revenue. Labs that serve as preferred providers of diagnostic testing data can help health systems, ordering physicians, pharmaceutical companies, and other organizations when they reuse lab test data to support evidence-based care and
Tag: diagnostic industry
EDITOR’S NOTE: Submitted by Lâle White, CEO of XIFIN, Inc., of Carlsbad, California, this letter describes the problems caused by the Medicare program’s failure, as of January 1, 2013, to be ready to process and reimburse lab test claims for more than 100 new molecular diagnostic CPT codes.
Everyone should read Scott Gottlieb, M.D.’s Forbes
CEO SUMMARY: In presenting this list of macro trends for clinical laboratories, several themes are in play. They range from a continued emphasis on improving lab operations to the need to acquire and deploy sophisticated information technology. During the next few years, the long-predicted retirement of Baby Boomers will kick in. That will aggravate the
CEO SUMMARY: It’s an important milestone for the clinical laboratory profession. Quest Diagnostics Incorporated South Florida, based in Deerfield Beach, Florida, earned the 2007 Florida Governor’s Sterling Award for quality. This is only the second laboratory in this country to win a state quality award. But that’s just part of the story. Guided by the
WHEN Danaher Corporation’s high bid for Vision Systems Limited of Melbourne, Australia, was accepted last month, it appeared to be simply another acquisition by a large U.S. manufacturer. But, in fact, there are four reasons this transaction is significant to pathologists in the United States and worldwide.
If approved by Vision’s shareholders later this year, the
CEO SUMMARY: In the space of just nine weeks, Siemens AG purchased Diagnostic Products Corp. (DPC) and Bayer Diagnostics. Siemens paid $1.86 billion and $5.31 billion, respectively, for the two invitro diagnostics (IVD) companies. Once it closes the acquisition of Bayer Diagnostics, Siemens will have the third largest IVD business in the world. Experts predict
CEO SUMMARY: Because cervical cancer screening involves more than 55 million Pap tests per year in the United States, it is a high-profile segment of the lab testing industry. HPV testing is making steady inroads into the cervical cancer screening process. Digene Corporation is the direct beneficiary of this, but Cytyc Corporation and TriPath Imaging
CEO SUMMARY: Diagnostic companies are undergoing the same consolidation wave as commercial laboratories and hospitals. Beckman’s acquisition of Coulter provides an early example of how diagnostics companies will use acquisitions to create a comprehensive product line. Other surprising mergers between diagnostic companies are expected.
CONSOLIDATION ACTIVITY WITHIN the diagnostic industry is about to intensify. As it